Home LiteratureArticle Details
PMID: 10449438 Published · ppublish English Comparative Study Journal Article

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

The Journal of clinical investigation ·Vol. 104 ·No. 4 ·1999-08-00 ·Pages 459-67

Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL

Abstract

We demonstrate an increase in graft-versus-host disease (GVHD) after experimental bone marrow transplant (BMT) when cyclophosphamide (Cy) is added to an otherwise well-tolerated dose (900 cGy) of total body irradiation (TBI). Donor T cell expansion on day +13 was increased after conditioning with Cy/TBI compared with Cy or TBI alone, although cytotoxic T lymphocyte (CTL) function was not altered. Histological analysis of the gastrointestinal tract demonstrated synergistic damage by Cy/TBI and allogeneic donor cells, which permitted increased translocation of LPS into the systemic circulation. TNF-alpha and IL-1 production in response to LPS was increased in BMT recipients after Cy/TBI conditioning. Neutralization of IL-1 significantly reduced serum LPS levels and GVHD mortality, but it did not affect donor CTL activity. By contrast, neutralization of TNF-alpha did not prevent GVHD mortality but did impair CTL activity after BMT. When P815 leukemia cells were added to the bone marrow inoculum, allogeneic BMT recipients given the TNF-alpha inhibitor relapsed at a significantly faster rate than those given the IL-1 inhibitor. To confirm that the role of TNF-alpha in graft versus leukemia (GVL) was due to effects on donor T cells, cohorts of animals were transplanted with T cells from either wild-type mice or p55 TNF-alpha receptor-deficient mice. Recipients of TNF-alpha p55 receptor-deficient T cells demonstrated a significant impairment in donor CTL activity after BMT and an increased rate of leukemic relapse compared with recipients of wild-type T cells. These data highlight the importance of conditioning in GVHD pathophysiology, and demonstrate that TNF-alpha is critical to GVL mediated by donor T cells, whereas IL-1 is not.

MeSH Terms
Animals Antigens, CD/genetics,immunology Bone Marrow Transplantation/adverse effects,immunology Cyclophosphamide/pharmacology Digestive System/injuries Female Graft vs Host Disease/etiology,immunology,prevention & control Graft vs Host Reaction/drug effects,immunology Interleukin-1/antagonists & inhibitors,immunology Mice Mice, Inbred C57BL Mice, Knockout Receptors, Tumor Necrosis Factor/genetics,immunology Receptors, Tumor Necrosis Factor, Type I T-Lymphocytes, Cytotoxic/immunology Transplantation Conditioning Transplantation, Homologous Tumor Necrosis Factor-alpha/antagonists & inhibitors,immunology Whole-Body Irradiation
Chemicals
Antigens, CD Interleukin-1 Receptors, Tumor Necrosis Factor Receptors, Tumor Necrosis Factor, Type I Tumor Necrosis Factor-alpha Cyclophosphamide
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Hill G R
Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Teshima T
Gerbitz A
Pan L
Cooke K R
Brinson Y S
Crawford J M
Ferrara J L
References (52)
52 references, click to expand
  1. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis.
    Hepatology. 1984 Jan-Feb;4(1):123-30 PMID: 6363248
  2. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma.
    J Immunol. 1996 Oct 1;157(7):2851-6 PMID: 8816389
  3. Comparison of murine lymphokine-activated killer cells, natural killer cells, and cytotoxic T lymphocytes.
    Cell Immunol. 1985 Oct 1;95(1):95-104 PMID: 3875426
  4. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats.
    Int J Immunopharmacol. 1986;8(1):53-62 PMID: 2420733
  5. Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.
    J Immunol. 1986 Oct 1;137(7):2380-4 PMID: 3489763
  6. Genetic nomenclature for loci controlling mouse lymphocyte antigens.
    Immunogenetics. 1987;25(2):71-8 PMID: 3817907
  7. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells.
    J Exp Med. 1987 Feb 1;165(2):515-30 PMID: 2950198
  8. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.
    J Exp Med. 1987 Oct 1;166(4):991-8 PMID: 3498791
  9. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha.
    Transplantation. 1989 Jun;47(6):1057-61 PMID: 2525289
  10. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.
    Cell. 1993 May 7;73(3):457-67 PMID: 8387893
  11. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.
    Blood. 1996 Oct 15;88(8):3230-9 PMID: 8963063
  12. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution.
    Transplantation. 1996 Oct 15;62(7):947-53 PMID: 8878389
  13. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL.
    Curr Opin Immunol. 1996 Oct;8(5):674-80 PMID: 8902393
  14. Chimerism and central tolerance.
    Curr Opin Immunol. 1996 Oct;8(5):694-703 PMID: 8902396
  15. Treatment with neutralizing antibodies specific for IL-1beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice.
    Diabetes. 1997 Jun;46(6):937-40 PMID: 9166662
  16. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide.
    J Clin Invest. 1997 Sep 1;100(5):1015-27 PMID: 9276718
  17. Cytokine cascades in acute graft-versus-host disease.
    Transplantation. 1997 Aug 27;64(4):553-8 PMID: 9293864
  18. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.
    Blood. 1997 Oct 15;90(8):3204-13 PMID: 9376604
  19. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.
    J Immunol. 1998 Jan 15;160(2):943-52 PMID: 9551933
  20. TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection.
    J Immunol. 1998 Jan 1;160(1):120-33 PMID: 9551964
  21. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.
    Blood. 1998 Jun 1;91(11):4051-5 PMID: 9596649
  22. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.
    J Clin Invest. 1998 Jul 1;102(1):115-23 PMID: 9649564
  23. The role of cytokines in acute graft-versus-host disease.
    Cytokines Cell Mol Ther. 1997 Dec;3(4):257-66 PMID: 9740354
  24. How do cytotoxic lymphocytes kill their targets?
    Curr Opin Immunol. 1998 Oct;10(5):581-7 PMID: 9794837
  25. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.
    Blood. 1998 Nov 15;92(10):3960-7 PMID: 9808590
  26. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.
    J Clin Invest. 1998 Nov 15;102(10):1882-91 PMID: 9819375
  27. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Blood. 1999 Apr 15;93(8):2738-47 PMID: 10194454
  28. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    J Clin Invest. 1999 Aug;104(3):317-25 PMID: 10430613
  29. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.
    J Exp Med. 1987 Nov 1;166(5):1280-9 PMID: 3316469
  30. Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T cells.
    J Immunol. 1990 Jun 15;144(12):4555-61 PMID: 2161875
  31. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.
    Blood. 1990 Nov 1;76(9):1867-71 PMID: 2224134
  32. Chemotherapy enhances endothelial cell reactivity to platelets.
    Clin Exp Metastasis. 1990 Nov-Dec;8(6):511-8 PMID: 2146053
  33. Nuclear magnetic resonance of hepatic graft-versus-host disease in mice.
    Transplantation. 1990 Dec;50(6):1011-8 PMID: 2256143
  34. Graft-versus-host disease.
    N Engl J Med. 1991 Mar 7;324(10):667-74 PMID: 1994250
  35. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
    Bone Marrow Transplant. 1991 Mar;7(3):193-8 PMID: 2059756
  36. A role for transforming growth factor-beta 1 in regulating natural killer cell and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus.
    J Immunol. 1991 Oct 15;147(8):2717-27 PMID: 1918986
  37. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo.
    J Immunol. 1992 Feb 1;148(3):766-71 PMID: 1530956
  38. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.
    J Exp Med. 1992 Feb 1;175(2):405-13 PMID: 1732411
  39. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Blood. 1992 Oct 1;80(7):1838-45 PMID: 1391947
  40. Cytokine dysregulation and acute graft-versus-host disease.
    Blood. 1992 Dec 15;80(12):2964-8 PMID: 1467511
  41. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens.
    Transplantation. 1993 Dec;56(6):1518-23 PMID: 8279027
  42. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury.
    J Pharmacol Exp Ther. 1994 Jan;268(1):42-6 PMID: 8301583
  43. The role of tumor necrosis factor and interferon gamma in graft-versus-host disease and related immunodeficiency.
    Transplantation. 1994 Jan;57(2):273-9 PMID: 8310520
  44. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration.
    Bone Marrow Transplant. 1994 Apr;13(4):473-7 PMID: 8019473
  45. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
    Blood. 1994 Aug 15;84(4):1342-8 PMID: 8049450
  46. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
    Blood. 1994 Sep 15;84(6):2036-43 PMID: 8081005
  47. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.
    Nature. 1994 Dec 8;372(6506):560-3 PMID: 7990930
  48. Differential effect of pre-transplant cytoreduction on recovery of day zero host circulating cells.
    Bone Marrow Transplant. 1994 Oct;14(4):623-30 PMID: 7858538
  49. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F).
    Blood. 1995 Aug 1;86(3):890-9 PMID: 7620183
  50. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease.
    J Exp Med. 1996 Feb 1;183(2):657-61 PMID: 8627178
  51. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
    J Exp Med. 1996 Jun 1;183(6):2645-56 PMID: 8676085
  52. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation.
    Hum Pathol. 1985 Apr;16(4):387-92 PMID: 3884482
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1999-08-00
Pages
459-67
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC408528
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com